What question did this study set out to answer?

To enhance the management of chemotherapy-induced nausea and vomiting (CINV) through optimized antiemetic therapy.

January 14, 2026memo - Magazine of European Medical Oncology0 citationsOpen Access

Antiemetic therapy

GJGeorg JeryczynskiMedical University of Vienna

Key Points

To enhance the management of chemotherapy-induced nausea and vomiting (CINV) through optimized antiemetic therapy.
Review of current antiemetic therapies, including serotonin and neurokinin-1 receptor antagonists.
Discussion of guideline-based prophylaxis strategies for CINV.
Evaluation of olanzapine's role in delayed-phase control and patient education efforts.
Improved control rates for CINV reported with serotonin and neurokinin-1 receptor antagonists.
Continued underutilization of guideline-based prophylaxis identified.
Enhanced patient education linked to better adherence to antiemetic protocols.

Abstract

Summary Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing adverse effects of antineoplastic therapy despite major advances in antiemetic management. The introduction of serotonin (5-HT3) and neurokinin‑1 (NK1) receptor antagonists has significantly improved control rates, although underutilization of guideline-based prophylaxis persists. Current recommendations emphasize tailoring therapy to the emetogenic potential of agents, with olanzapine now incorporated for improved delayed-phase control. Challenges remain in breakthrough and delayed CINV, steroid-sparing regimens, and individualized risk-adapted prophylaxis. Optimizing adherence to ASCO, NCCN, and MASCC/ESMO guidelines and patient education are key to enhancing outcomes and quality of life during chemotherapy.

问 AI

Bookmark

View Full Paper

Cite This Study

Georg Jeryczynski (Mon,) studied this question.

synapsesocial.com/papers/6966e73513bf7a6f02bffc0e https://doi.org/https://doi.org/10.1007/s12254-025-01098-5

问 AI

Bookmark

View Full Paper